신경통 치료 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Neuralgia Treatment Market Growth & Trends:

The global neuralgia treatment market size is expected to reach USD 3.43 billion in 2030 and is projected to grow at a CAGR of 6.7% from 2025 to 2030. The rising geriatric population, increasing incidence of trigeminal neuralgia, and the growing prevalence of diabetes are the key factors driving the market. Neuralgia is a burning, stabbing, and severe pain due to a damaged or irritated nerve.

The chronic pain in the nerves can occur due to various factors such as infection, diabetes, aging, multiple sclerosis, or any similar disorders that damage the myelin sheath protecting certain nerves. Tumor compressing the trigeminal nerve can also cause the disorder. The prevalence of chronic pain in the trigeminal nerve increases with the aging population. According to the estimates published by the WHO, the geriatric population is anticipated to rise from 900.0 million in 2015 to 2.0 billion in 2050. The geriatric population is prone to many diseases such as diabetes and trigeminal neuralgia.

As per the American Association of Neuromuscular and Electrodiagnostic Medicine, the disorder usually affects the population aged 50 years or older. It also reported that women are more prone to trigeminal neuralgia than men. As per the study, The Patient's Journey Through Trigeminal Neuralgia published by the International Association for The Study of Pain (IASP), the incidence rate of the disorder in the general population is 3.4 to 5.9 per 100,000 population. It also reported that the incidence rate is comparatively higher in the geriatric population. Such factors are expected to boost market growth over the forecast period. Stereotactic radiosurgery and microvascular decompression are the two most common procedures being adopted to treat the disorder.

Neuralgia Treatment Market Report Highlights:

• The surgery segment dominated the market and accounted for a share of 64.8% in 2024. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a key driver for the segment
• The drug-based segment is expected to grow at the fastest CAGR of 7.0% over the forecast period
• The hospital & clinics segment accounted for the largest market revenue share in 2024. Adopting advanced, non-invasive technologies in hospitals and clinics drives the market by providing more accurate and targeted treatments
• The ambulatory surgery centers segment is expected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Neuralgia Treatment Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Neuralgia Treatment Market: Treatment Business Analysis

• 4.1. Treatment Market Share, 2024 & 2030
• 4.2. Treatment Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
• 4.4. Drug Based
  • 4.4.1. Drug based market, 2018 - 2030 (USD Million)
  • 4.4.2. Anticonvulsant medicines
    • 4.4.2.1. Anticonvulsant medicines market, 2018 - 2030 (USD Million)
  • 4.4.3. Tricyclic antidepressants
    • 4.4.3.1. Tricyclic antidepressants market, 2018 - 2030 (USD Million)
• 4.5. Surgery
  • 4.5.1. Surgery market, 2018 - 2030 (USD Million)
  • 4.5.2. Radiofrequency Thermal Lesioning
    • 4.5.2.1. Radiofrequency thermal lesioning market, 2018 - 2030 (USD Million)
  • 4.5.3. Stereotactic Radiosurgery
    • 4.5.3.1. Stereotactic radiosurgery market, 2018 - 2030 (USD Million)
  • 4.5.4. Microvascular Decompression
    • 4.5.4.1. Microvascular decompression market, 2018 - 2030 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. Neuralgia Treatment Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Hospital & Clinics
  • 5.4.1. Hospital & clinics market, 2018 - 2030 (USD Million)
• 5.5. Ambulatory Surgery Centers
  • 5.5.1. Ambulatory surgery centers market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 6. Neuralgia Treatment Market: Country Estimates & Trend Analysis by Product and Technology

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key country dynamic
    • 6.4.2.2. Regulatory framework
    • 6.4.2.3. Competitive insights
    • 6.4.2.4. U.S. neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key country dynamic
    • 6.4.3.2. Regulatory framework
    • 6.4.3.3. Competitive insights
    • 6.4.3.4. Canada neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key country dynamic
    • 6.4.4.2. Regulatory framework
    • 6.4.4.3. Competitive insights
    • 6.4.4.4. Mexico neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key country dynamic
    • 6.5.2.2. Regulatory framework
    • 6.5.2.3. Competitive insights
    • 6.5.2.4. UK neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key country dynamic
    • 6.5.3.2. Regulatory framework
    • 6.5.3.3. Competitive insights
    • 6.5.3.4. Germany neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key country dynamic
    • 6.5.4.2. Regulatory framework
    • 6.5.4.3. Competitive insights
    • 6.5.4.4. France neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key country dynamic
    • 6.5.5.2. Regulatory framework
    • 6.5.5.3. Competitive insights
    • 6.5.5.4. Italy neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key country dynamic
    • 6.5.6.2. Regulatory framework
    • 6.5.6.3. Competitive insights
    • 6.5.6.4. Spain neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Russia
    • 6.5.7.1. Key country dynamic
    • 6.5.7.2. Regulatory framework
    • 6.5.7.3. Competitive insights
    • 6.5.7.4. Russia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key country dynamic
    • 6.5.8.2. Regulatory framework
    • 6.5.8.3. Competitive insights
    • 6.5.8.4. Denmark neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key country dynamic
    • 6.5.9.2. Regulatory framework
    • 6.5.9.3. Competitive insights
    • 6.5.9.4. Sweden neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.10. Norway
    • 6.5.10.1. Key country dynamic
    • 6.5.10.2. Regulatory framework
    • 6.5.10.3. Competitive insights
    • 6.5.10.4. Norway neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key country dynamic
    • 6.6.2.2. Regulatory framework
    • 6.6.2.3. Competitive insights
    • 6.6.2.4. Japan neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key country dynamic
    • 6.6.3.2. Regulatory framework
    • 6.6.3.3. Competitive insights
    • 6.6.3.4. China neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key country dynamic
    • 6.6.4.2. Regulatory framework
    • 6.6.4.3. Competitive insights
    • 6.6.4.4. India neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key country dynamic
    • 6.6.5.2. Regulatory framework
    • 6.6.5.3. Competitive insights
    • 6.6.5.4. Australia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamic
    • 6.6.6.2. Regulatory framework
    • 6.6.6.3. Competitive insights
    • 6.6.6.4. Thailand neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. South Korea
    • 6.6.7.1. Key country dynamic
    • 6.6.7.2. Regulatory framework
    • 6.6.7.3. Competitive insights
    • 6.6.7.4. South Korea neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key country dynamic
    • 6.7.2.2. Regulatory framework
    • 6.7.2.3. Competitive insights
    • 6.7.2.4. Brazil neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key country dynamic
    • 6.7.3.2. Regulatory framework
    • 6.7.3.3. Competitive insights
    • 6.7.3.4. Argentina neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key country dynamic
    • 6.8.2.2. Regulatory framework
    • 6.8.2.3. Competitive insights
    • 6.8.2.4. South Africa neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key country dynamic
    • 6.8.3.2. Regulatory framework
    • 6.8.3.3. Competitive insights
    • 6.8.3.4. Saudi Arabia neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key country dynamic
    • 6.8.4.2. Regulatory framework
    • 6.8.4.3. Competitive insights
    • 6.8.4.4. UAE neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key country dynamic
    • 6.8.5.2. Regulatory framework
    • 6.8.5.3. Competitive insights
    • 6.8.5.4. Kuwait neuralgia treatment market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. GSK plc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Product benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. Pfizer Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Product benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. Novartis AG
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Product benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. Biogen
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Product benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. Zydus Group (Cadila Healthcare Limited)
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Product benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. H. Lundbeck A/S
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Product benchmarking
    • 7.5.6.4. Strategic initiatives